Novel Management of Masticatory Myositis in Three Dogs with a Selective Janus Kinase (JAK-1) Inhibitor.

Masticatory myositis (MM) is an inflammatory myopathy reported in dogs and is characterized by inflammation of the masticatory muscles (temporalis, masseter, and pterygoid muscles). Immunosuppressive therapy is the current recommended treatment for MM and may involve glucocorticoids, cyclosporine, azathioprine, mycophenolate mofetil, leflunomide, or a combination of these treatments that are slowly tapered to the lowest effective dose. However, side effects from multimodal medical therapy and complications associated with MM relapses have been reported. The purpose of this case series was to report oclacitinib as a treatment alternative to traditional medical management of MM. The intent of this alternative is to manage side effects from glucocorticoid use. Oclacitinib (1mg/kg per os q12h) was used solely for treatment of MM in three dogs. The dogs were followed up to >6 months after oclacitinib administration. An increase in oral range of motion, as determined by gape angle, was noted in all three dogs. However, a corresponding drop in antibody titers (2M fiber) did not occur. All dogs showed improvement in overall clinical management of MM, side effects from glucocorticoids, and clinical signs related to chronic prednisone use. Larger controlled trials with consistent measurements (interincisal distance, gape angle) and 2M fiber antibody titers are indicated to further assess validation of oclacitinib treatment of MM. The clinical outcome of all dogs was considered successful.

Application of a maxillary transfacial approach to the caudal oral cavity and orbitozygomaticomaxillary complex in dogs.

Surgical access and visualization for excision of large pathologic lesions of the orbitozygomaticomaxillary complex (OZMC) and caudal oral cavity can be a challenge in veterinary oromaxillofacial surgery and may limit one's ability to perform such procedures. Combined intra- and extra-oral approaches as well as commissurotomy have been advocated in the past. However, each of these approaches present unique limitations specific to each approach. A transfacial approach that ameliorated these limitations could be advantageous. In this descriptive cohort study, we investigate the application and outcomes of a maxillary transfacial approach to the OZMC and caudal oral cavity in six client-owned dogs. The approach is based on the Weber-Ferguson approach for human applications and provided excellent exposure of the intended region in all six patients. We contend the maxillary transfacial approach provides some advantages to the more conventional combined intra-oral/extra-oral approach or commissurotomy for excision of large pathologic lesions of the OZMC and caudal oral cavity.

Corrigendum: Analysis of the approach angle to medial orbitotomy that avoids accidental neurotrauma in the mesaticephalic dog skull utilizing 3D computer models and virtual surgical planning.

[This corrects the article DOI: 10.3389/fvets.2023.1185454.].

Analysis of the approach angle to medial orbitotomy that avoids accidental neurotrauma in the mesaticephalic dog skull utilizing 3D computer models and virtual surgical planning.

This study was conducted to determine an approach angle to medial orbitotomy that avoids accidental neurotrauma in mesaticephalic dogs. Medical records of dogs with mesaticephalic skulls that were presented to the veterinary medical teaching hospital for head computed tomography (CT) between September 2021 and February 2022 were reviewed. Descriptive data were queried, and CT findings were analyzed. Dogs greater than 20 kg and possessing a disease-free orbitozygomaticomaxillary complex (OZMC) on at least one side of the skull were included in this study. Digital imaging and communications in medicine (DICOM) files of head CT studies were imported into medical modeling software, and the safe approach angle for medial orbitotomy was determined using three-dimensional (3D) computer models and virtual surgical planning (VSP) principles. Angles were measured along the ventral orbital crest (VOC) from the rostral cranial fossa (RCF) to the rostral alar foramen (RAF). The safe approach angle at four points from rostral to caudal along the VOC was measured. The results at each location were reported as mean, median, 95% CI, interquartile ranges, and distribution. The results were statistically different at each location and generally increased from rostral to caudal. The variances between subjects and the differences between locations were large enough to suggest a standard safe approach angle in mesaticephalic dogs cannot be determined and should be measured for each patient. A standardized approach angle to medial orbitotomy is not possible in the mesaticephalic dog. Computer modeling and VSP principles should be implemented as part of the surgical planning process to accurately measure the safe approach angle along the VOC.

Comparison of short-, intermediate-, and long-term results between dogs with tracheal collapse that underwent multimodal medical management alone and those that underwent tracheal endoluminal stent placement.

OBJECTIVE: To compare short-, intermediate-, and long-term results between dogs with tracheal collapse (TC) that received multimodal medical management only and those that underwent tracheal endoluminal stent placement. ANIMALS: 159 dogs with TC that underwent medical management only (MM group; n = 84) or were surgically managed by stent placement (SM group; 75). PROCEDURES: Medical records of dogs with TC that underwent medical management only or stent placement at a referral hospital between September 1, 2009, and August 1, 2018, were reviewed. Data regarding signalment, information relevant to TC, and outcome were extracted from the records and aggregated into short-, intermediate-, and long-term follow-up periods for analysis. Descriptive data and median survival times (MSTs) were compared between the MM and SM groups. RESULTS: Clinical signs of dogs in the MM group generally improved during the short term but regressed and worsened over time. The proportion of dogs with malformation-type TC that underwent stent placement (38/43 [88%]) was significantly greater than the proportion of dogs with traditional-type TC that underwent stent placement (37/107 [35%]). The MST from TC diagnosis was 3.7 years for the MM group and 5.2 years for the SM group. For dogs with severe disease, the MST was 12 days for medically managed dogs and 1,338 days for dogs that underwent stent placement. CONCLUSIONS AND CLINICAL RELEVANCE: Multimodal medical management alleviated clinical signs for months to years in dogs with mild to moderate TC disease, but stent placement should be considered for dogs with severe disease.

Variability in Recommendations for Cervical Lymph Node Pathology for Staging of Canine Oral Neoplasia: A Survey Study.

There is no clear guideline regarding the indication for routine lymph node extirpation and pathologic evaluation during staging of canine oral tumors, despite a relatively high reported nodal metastatic rate for select tumor types. It is particularly unclear if clinicians recommend removal of lymph nodes only when there is confirmation of metastasis, defined as the N+ neck, or if elective neck dissection (END) is routinely recommended to confirm the true pathologic metastatic status of lymph nodes in the clinical N0 neck (no evidence of metastasis on clinical staging with diagnostic imaging or cytology). When clinicians are recommending END as a staging tool to confirm nodal status, there is also ambiguity regarding the surgical extent for subsequent histopathologic evaluation. The objective of this cross-sectional survey study was to determine the current recommendations given by practicing specialists regarding lymph node removal for dogs with oral tumors. Overall, 87 responses were obtained from 49 private practices (56%) and 38 academic institutions (44%). Respondents identified as oncologists (44%, N = 38), soft tissue surgeons (40%, N = 35), and dentists (16%, N = 14). Regardless of tumor type and stage, extirpation and histopathology were most commonly recommended in the clinical N+ neck only. The recommendation to routinely perform END in the N0 neck was significantly associated with tumor type. Bilateral removal of the mandibular and retropharyngeal lymph nodes was recommended more often for oral malignant melanoma (OMM) than for oral squamous cell carcinoma (OSCC; p ≤ 0.0039) or for oral fibrosarcoma (OFSA; p ≤ 0.0007). The likelihood of recommending END increased with increasing tumor size. Academic clinicians were significantly (p < 0.01) more likely to recommend END compared to private practitioners for canine T1-T3 OMM, T3 OSCC, T2 OFSA, and MCT. This study highlights the variability in recommendations for lymph node pathology for dogs with oral tumors. While tumor type and size influenced the decision to pursue END, it was not routinely recommended, even for tumor types with a known propensity for metastasis. Prospective studies are warranted to determine the potential diagnostic and therapeutic value of END in the N0 neck in veterinary patients such that a consensus approach can be made.